Labcorp: Labcorp Launches Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Labcorp announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test further expands Labcorp's leading blood-based biomarker portfolio for Alzheimer's disease and dementia. The pTau-217/Beta Amyloid 42 Ratio supports neurologists, dementia specialists and their patients by offering results that are comparable to positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing obtained through lumbar puncture. Labcorp's test meets performance criteria to confirm the presence of amyloid pathology consistent with Alzheimer's disease, and, in connection with clinical findings, supports an accelerated path to diagnosis in patients being evaluated for Alzheimer's disease and other causes of cognitive decline. Key Features of Labcorp's pTau-217/beta Amyloid 42 Ratio. A first-of-its-kind immunoassay measuring two distinct biomarkers known as indicators of Alzheimer's disease: pTau-217 and Beta Amyloid 42, in ratio. Offers a sensitivity and specificity of 95%, which is substantially equivalent to the performance of amyloid PET imaging and CSF testing. Patient blood draws can be completed in a physician's office or any of Labcorp's more than 2,000 Patient Service Centers (PSCs) nationwide. Available for use in clinical trials in addition to clinical patient care. Labcorp will present data related to the pTau-217/Alpha Amyloid 42 Ratio at the American Association of Neurology's 2025 Annual Meeting April 5 - 9 in San Diego. Labcorp announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test further expands Labcorp's leading blood-based biomarker portfolio for Alzheimer's disease and dementia. The pTau-217/Beta Amyloid 42 Ratio supports neurologists, dementia specialists and their patients by offering results that are comparable to positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing obtained through lumbar puncture. Labcorp's test meets performance criteria to confirm the presence of amyloid pathology consistent with Alzheimer's disease, and, in connection with clinical findings, supports an accelerated path to diagnosis in patients being evaluated for Alzheimer's disease and other causes of cognitive decline. Key Features of Labcorp's pTau-217/beta Amyloid 42 Ratio. A first-of-its-kind immunoassay measuring two distinct biomarkers known as indicators of Alzheimer's disease: pTau-217 and Beta Amyloid 42, in ratio. Offers a sensitivity and specificity of 95%, which is substantially equivalent to the performance of amyloid PET imaging and CSF testing. Patient blood draws can be completed in a physician's office or any of Labcorp's more than 2,000 Patient Service Centers (PSCs) nationwide. Available for use in clinical trials in addition to clinical patient care. Labcorp will present data related to the pTau-217/Alpha Amyloid 42 Ratio at the American Association of Neurology's 2025 Annual Meeting April 5 - 9 in San Diego.